Publication | Closed Access
Extended interval dosing of natalizumab in multiple sclerosis
146
Citations
21
References
2016
Year
Dosing intervals up to 8 weeks 5 days did not diminish effectiveness of NTZ therapy. Further monitoring is ongoing to evaluate if the risk of PML is reduced in patients on EID.
| Year | Citations | |
|---|---|---|
Page 1
Page 1